Here's Why Johnson & Johnson (JNJ) is a Strong Value Stock

Company Overview - Johnson & Johnson (JNJ) has a diversified business model, operating through pharmaceuticals and medical devices divisions, with over 275 subsidiaries, which enhances its resilience against economic cycles [11] - The company has 26 platforms generating more than 1 billion in annual sales and maintains one of the largest R&D budgets among pharmaceutical companies [11] Investment Ratings - JNJ is currently rated 3 (Hold) on the Zacks Rank, with a VGM Score of B, indicating a solid position but not a strong buy [12] - The Value Style Score for JNJ is B, supported by attractive valuation metrics, including a forward P/E ratio of 14.45, which may appeal to value investors [12] Earnings Estimates - In the last 60 days, four analysts have revised their earnings estimates higher for fiscal 2025, with the Zacks Consensus Estimate increasing by 0.04 to $10.58 per share [12] - JNJ has demonstrated an average earnings surprise of 4.4%, indicating a positive trend in earnings performance [12] Conclusion - With a solid Zacks Rank and favorable Value and VGM Style Scores, JNJ is recommended for investors' consideration [13]